Can-Fite BioPharma (CANF) Registration Filing summary

Company overview and business model

• Advanced clinical-stage biopharmaceutical company developing orally bioavailable small molecule therapeutics for cancer, liver, and inflammatory diseases, leveraging the A3 adenosine receptor (A3AR) as a therapeutic target.

• Product pipeline includes CF101 (Piclidenoson) for psoriasis, CF102 (Namodenoson) for hepatocellular carcinoma (HCC) and MASH, and CF602 for erectile dysfunction, with additional preclinical candidates for other indications.

• Out-licensing agreements for key product candidates in multiple global territories and ongoing pivotal Phase III and II trials for lead indications.

• Strategy focuses on advancing clinical pipeline, in-licensing synergistic technologies, targeting major global markets, and commercializing through out-licensing and partnerships.

Financial performance and metrics

• April 2025 registered direct offering raised approximately $3.0 million in gross proceeds at $1.20 per ADS.

• As of July 22, 2025, 3,988,296,093 Ordinary Shares were outstanding, represented by 13,294,320 ADSs.

• Pro forma as adjusted net tangible book value per ADS after the offering would be $0.73, with immediate dilution of $0.29 per ADS to new investors at the assumed offering price.

• Estimated net proceeds from the offering, assuming maximum sale, are approximately $4.20 million after fees and expenses.

Use of proceeds and capital allocation

• Net proceeds intended for funding research and development, clinical trials, and general corporate purposes, with management retaining broad discretion over allocation.

• Proceeds, together with existing cash, expected to fund operations through various dates in 2026–2027 depending on the amount raised.

• Pending use, proceeds may be invested in capital preservation instruments.